Literature DB >> 14652070

Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding.

Stacy Seeley1, Lidija Covic, Suzanne L Jacques, James Sudmeier, James D Baleja, Athan Kuliopulos.   

Abstract

Protease-activated G protein-coupled receptors (PAR1-4) are tethered-ligand receptors that are activated by proteolytic cleavage of the extracellular domain (exodomain) of the receptor. PAR1, the prototypic member of the PAR family, is the high-affinity thrombin receptor of platelets and vascular endothelium and plays a critical role in blood coagulation, thrombosis, and inflammation. Here, we describe the solution structure of the thrombin-cleaved exodomain of PAR1. The side chains of a hydrophobic hirudin-like (Hir) sequence and adjacent anionic motif project into solution. Docking of the exodomain Hir sequence to exosite I of thrombin reveals that the tethered ligand in the cleaved exodomain bends away from thrombin, leaving its active site available to another large macromolecular substrate. The N-terminal ligand is longer than anticipated and forms an intramolecular complex with a region located in the C terminus of the exodomain. Mutational analysis confirmed that this C-terminal region is a ligand binding site for both intra- and intermolecular ligands. A lipidated-ligand binding site peptide was found to be an effective inhibitor of thrombin-induced platelet aggregation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652070     DOI: 10.1016/j.chembiol.2003.10.014

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  33 in total

1.  Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1.

Authors:  Prafull S Gandhi; Zhiwei Chen; Enrico Di Cera
Journal:  J Biol Chem       Date:  2010-03-17       Impact factor: 5.157

Review 2.  Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases.

Authors:  Thomas J Wilson; Rakesh K Singh
Journal:  Biochim Biophys Acta       Date:  2007-11-26

3.  Structural identification of the pathway of long-range communication in an allosteric enzyme.

Authors:  Prafull S Gandhi; Zhiwei Chen; F Scott Mathews; Enrico Di Cera
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

4.  Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics.

Authors:  Ping Zhang; Andrew J Leger; James D Baleja; Rajashree Rana; Tiffany Corlin; Nga Nguyen; Georgios Koukos; Andrew Bohm; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2015-05-01       Impact factor: 5.157

5.  Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.

Authors:  Rajashree Rana; Tianfang Huang; Georgios Koukos; Elizabeth K Fletcher; Susan E Turner; Andrew Shearer; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Kevin P Bliden; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-05       Impact factor: 8.311

Review 6.  The domino effect triggered by the tethered ligand of the protease activated receptors.

Authors:  Xu Han; Marvin T Nieman
Journal:  Thromb Res       Date:  2020-08-04       Impact factor: 3.944

7.  PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models.

Authors:  Travis P Barr; Chris Garzia; Srijoy Guha; Elizabeth K Fletcher; Nga Nguyen; Adam J Wieschhaus; Lluis Ferrer; Lidija Covic; Athan Kuliopulos
Journal:  J Invest Dermatol       Date:  2018-10-01       Impact factor: 8.551

8.  Characterization of a new peptide agonist of the protease-activated receptor-1.

Authors:  Yingying Mao; Jianguo Jin; Satya P Kunapuli
Journal:  Biochem Pharmacol       Date:  2007-09-08       Impact factor: 5.858

9.  Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin.

Authors:  Andrew M Shearer; Rajashree Rana; Karyn Austin; James D Baleja; Nga Nguyen; Andrew Bohm; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2016-09-09       Impact factor: 5.157

10.  PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study.

Authors:  Norma A Hernández; Elma Correa; Esther P Avila; Teresa A Vela; Víctor M Pérez
Journal:  J Transl Med       Date:  2009-06-18       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.